Article

Efficient inhibition of cell proliferation and promotion of apoptosis requires continuous treatment with abemaciclib

2021-11-15

Abstract excerpt

Abemaciclib is an oral, selective cyclin-dependent kinase 4 & 6 inhibitor (CDK4 & 6i), approved for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) as monotherapy for endocrine refractory disease, and with endocrine therapy (ET) for initial treatment and after progression on ET. Abemaciclib has also shown clinical activity in combination with...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8981deff-abc8-56e9-b284-5768358810b9
DOI: 10.1101/2021.11.15.468648

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficient inhibition of cell proliferation and promotion of apoptosis requires continuous treatment with abemaciclibDOI 10.1101/2021.11.15.468648Read

Biological specificity of CDK4/6 inhibitors: dose response relationship,in vivosignaling, and composite response signatureSemantic proximity Read

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunitiesSemantic proximity Read

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological ConditionsSemantic proximity Read

Targeting CDK4/6 in patients with cancerSemantic proximity Read

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancerSemantic proximity Read

The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assaysSemantic proximity Read

Elacestrant Plus Alpelisib in an ESR1 and PIK3CA Co-mutated and Heavily Pretreated Metastatic Breast Cancer: The First Case for Combination Efficacy and SafetySemantic proximity Read

Spectrum and Degree of CDK Drug Interactions Predicts Clinical PerformanceSemantic proximity Read

The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assaysSemantic proximity Read

Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas.Semantic proximity Read

Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway SignalingSemantic proximity Read

Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture modelsSemantic proximity Read